Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 51 - 100 out of 23,917

Document Document Title
WO/2018/105550A1
Provided is an amyotrophy inhibiting composition that comprises one or more kinds of peptides as active ingredient(s), said peptides being selected from the group consisting of tripeptides DIY, IYN, YNP, NPQ, DFY, DIF, FYN, IFN, FNP and ...  
WO/2018/105630A1
The present invention pertains to: a drug for preventing and/or treating cognitive dysfunction and/or a neurodegenerative disease accompanied by accumulation of prionoids, said drug comprising hemagglutinating virus of Japan envelope as ...  
WO/2018/099946A1
The present invention relates to novel bicyclic nucleosides and oligomers prepared therefrom. In particular, the present invention relates to a compound of formula (I), wherein one of T1 and T2 is OR1 or OR2; and the other of T1 and T2 i...  
WO/2018/101398A1
The present invention provides a pharmaceutical composition for use in the treatment or prevention of inflammatory bowel disease (IBD). More particularly, the present invention provides a pharmaceutical composition that contains apelin o...  
WO/2018/096100A1
The present invention provides a new use for cannabinoids in the prevention of pre-cachexia or cachexia in a patient suffering from cancer, wherein said cannabinoid is administered at low dosage and wherein administration is started prio...  
WO/2018/097733A3
A composition for the prevention and/or treatment of chronic fatigue syndrome (CFS)/ myalgia encephalomyelitis (ME) / systemic exertion intolerance disease (SEID) is described. Also described is a method for diagnosis of a patient with c...  
WO/2018/097733A2
A composition for the prevention and/or treatment of chronic fatigue syndrome (CFS)/ myalgia encephalomyelitis (ME) / systemic exertion intolerance disease (SEID) is described. Also described is a method for diagnosis of a patient with c...  
WO/2018/091688A1
The present invention relates to skeletal muscle hypertrophy inducers as well as their uses to promote skeletal muscle regeneration, to prevent skeletal muscle atrophy, or in the treatment or prevention of a disease or injury resulting i...  
WO/2018/090792A1
Disclosed are a selective Bruton's tyrosine kinase (BTK) inhibitor compound, a pharmaceutical composition, a preparation and the use thereof in the preparation of a drug for treating diseases, disorders or conditions benefiting from the ...  
WO/2018/091691A1
The present invention relates to LSD1 inhibitors and their uses as skeletal muscle hypertrophy inducers as well as to promote skeletal muscle regeneration, to prevent skeletal muscle atrophy, or in the treatment or prevention of a diseas...  
WO/2018/091689A1
The present invention relates to skeletal muscle hypertrophy inducers as well as their uses to promote skeletal muscle regeneration, to prevent skeletal muscle atrophy, or in the treatment or prevention of a disease or injury resulting i...  
WO/2018/088501A1
Provided is a method for inducing differentiation of pluripotent stem cells into somatic cells using a medium containing heparin binding growth factor, characterized by comprising contacting starting cells with a conjugate in which a lam...  
WO/2018/083271A1
The present application is concerned with methods for increasing the bioavailability and/or activity of agents and in particular allows selective targeting of an agent to, or via, the liver or allows the liver to be bypassed. By selectin...  
WO/2018/079719A1
The purpose of the invention is to provide a composition that has high biological safety and contributes to the activation of PGC-1α. Also, the purpose of the invention is to provide a use for said composition for activating PGC-1α and...  
WO/2018/078134A1
The present invention relates to compositions and methods for the treatment of myotonic dystrophy.  
WO/2018/077310A1
Disclosed is a vitamin C sodium-containing effervescent tablet, comprising the following components in parts by weight: 200-1120 parts of vitamin C sodium, 560-1300 parts of tartaric acid, 600-1500 parts of sodium bicarbonate, and 200-60...  
WO/2018/079715A1
The purpose of the invention is to provide a composition that has high biological safety and contributes to the inhibition of FOXO1 activity. Also, the purpose of the invention is to provide a use for said composition for inhibiting FOXO...  
WO/2018/076060A1
Methods and compositions for producing mature myotubes are provided herein. In some instances, the method involves contacting a myoblast in an in vitro culture with a compound, wherein the contacting the myoblast in the in vitro culture ...  
WO/2018/076107A1
In one aspect, there is provided a method of treating, prophylaxis, or amelioration of a neurological disease by administering to a subject in need thereof minocycline, or a functional derivative thereof, and hydroxychloroquine, or a fun...  
WO/2018/078131A1
The present invention relates to compositions and methods for the treatment of myotonic dystrophy.  
WO/2018/076108A1
ABSTRACT In one aspect, there is provided a method of treating, prophylaxis, or amelioration of a neurological disease by administering to a subject in need thereof one or more compounds described herein. In a specific example, the neuro...  
WO/2018/073414A1
The invention concerns the use of Lepista flaccida intended for treating a disease caused by a nonsense mutation of a gene resulting in the premature introduction of a UGA and/or UAA stop codon. It also concerns a Lepista flaccida extrac...  
WO/2018/075858A1
This disclosure features the use of one or more indazole-3-carboxamide compounds or salts or analogs thereof, in the treatment of one or more diseases or conditions independently selected from the group consisting of a tendinopathy, derm...  
WO/2018/070510A1
Provided is an agent developed to be capable of alleviating and suppressing muscle atrophy or muscle mass reduction, even for the elderly and even without requiring exercise, by inducing myogenesis. Provided is a composition for treating...  
WO/2018/066427A1
The present invention addresses the problem of providing a composition for preventing and/or treating neurodegenerative diseases and cerebral infarction and a composition for improving learning disorders. Provided is a composition that c...  
WO/2018/066394A1
Provided is a composition that improves the flexibility of muscles by oral intake. The composition, which makes muscles flexible by oral intake, comprises an n-3 highly unsaturated fatty acid as an active ingredient. The n-3 highly unsat...  
WO/2018/067879A1
In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of an ALK4 receptor and an extracellular domain of ActRIIB. In certain aspects, such soluble ALK4:ActRIIB complexes ...  
WO/2018/060418A1
The present invention relates to a substance selected from the group comprising irinotecan, an irinotecan active metabolite, 5-fluoro-uracile, a pharmaceutical salt thereof and a mixture thereof, for use in the treatment of fibrosis.  
WO/2018/053653A1
The present matter relates to compositions comprising Teneurin C-terminal Associated Peptide – 1 (TCAP-1) and methods and uses of same for enhancing and/or restoring muscle function.  
WO/2018/053632A1
Methods for modifying a dystrophin gene are disclosed, for restoring dystrophin expression within a cell having an endogenous frameshift or nonsense mutation within the dystrophin gene. The methods comprise introducing a first cut within...  
WO/2018/056871A1
The invention relates to the field of molecular medicine. The subject matter of the invention is a use of oligonucleotide analogues, where one or more phosphodiester groups are substituted with a phosphoryl guanidine group, and derivativ...  
WO/2018/052114A1
The present invention pertains to a pharmaceutical composition which contains a morphinan derivative exhibiting the action of an opioid δ receptor agonist. By administering the pharmaceutical composition provided by the present inventio...  
WO/2018/051355A1
Methods of treating Duchenne muscular dystrophy (DMD), as well as methods of reducing the dose of steroids used to treat DMD are provided. Kits comprising tamoxifen and citrulline, arginine or a combination thereof, are also provided.  
WO/2018/052082A1
This Lin28a activator includes, as an active ingredient, a polysaccharide which contains at least one substance selected from the group consisting of ribose, xylose, and derivatives of each. A monocyte dedifferentiation inducer includes,...  
WO/2018/053004A2
Pharmaceutical compositions that stabilize a Clostridial toxin active ingredient are described. The compositions can be liquid or solid compositions, and comprise a surfactant and an antioxidant. In some embodiments, the compositions com...  
WO/2018/053280A1
The subject invention provides a method for treating a subject afflicted with Rett syndrome comprising administering to the subject an effective amount of pridopidine so as to thereby treat the subject.  
WO/2018/053004A3
Pharmaceutical compositions that stabilize a Clostridial toxin active ingredient are described. The compositions can be liquid or solid compositions, and comprise a surfactant and an antioxidant. In some embodiments, the compositions com...  
WO/2018/047894A1
Provided is a novel antibody. According to the present invention, a monoclonal antibody or a binding fragment thereof binds to domain 3 of a human LAG-3, and has the properties described in (i) and (vi) and one or more of the properties ...  
WO/2018/041942A1
Embodiments of the invention are directed to new polymer linked multimeric guanosine-3', 5'-cyclic monophosphate (cGMP) analogues that modulate the cGMP-signaling system, preferably having activating properties, and more preferably being...  
WO/2018/041563A1
The present invention relates to novel substituted phenoxy- and benzyloxy-piperidine compounds of formula (I) having P2X7 receptor (P2X7) antagonistic properties, pharmaceutical compositions comprising these compounds, chemical processes...  
WO/2018/042141A1
The present invention concerns a tryptophan metabolite chosen from kynurenic acid, anthranilic acid, quinolinic acid, picolinic acid, quinaldic acid and the mixtures of same or an enantiomer, diastereoisomer, hydrate, solvate, tautomer, ...  
WO/2018/043694A1
The present invention provides a composition for improving muscular endurance, which is composed of nutrients, can be ingested safely and can improve muscular endurance easily within a short time and with high efficiency. The composition...  
WO/2018/040627A1
Use of catalpol in preparation of a drug for preventing and treating or delaying the onset of myasthenia and/or amyotrophy, including myasthenia and/or amyotrophy caused by diabetes, and myasthenia and/or amyotrophy caused by defect of d...  
WO/2018/043714A1
The purpose of the present invention is to efficiently produce microglia from a pluripotent stem cells. Provided is a method for producing microglia from pluripotent stem cells, comprising the following steps: (a) a step of co-culturing ...  
WO/2018/042330A1
Methods of improving physical performance and endurance include administering a capsicum composition to a subject. More particularly the methods include administration of an effective amount of a capsicum composition including capsaicino...  
WO/2018/043476A1
Provided is a therapeutic agent for amyotrophic lateral sclerosis, comprising: a compound represented by formula (1) (in formula (1), R1 each independently represents an alkyl group containing 1-6 carbon atoms or a 4-hydroxyphenethyl gro...  
WO/2018/038265A1
The present invention provides: a novel use of a specific bicyclic nitrogenated heterocyclic compound as a PDE7 inhibitor; a novel bicyclic nitrogenated heterocyclic compound having a PDE7 inhibition activity, a method for producing the ...  
WO/2018/038255A1
The purpose of the present invention is to provide crystals of a compound that exhibits an analgesic action against neuropathic pain and/or fibromyalgia, the crystals being useful as pharmaceuticals. The present invention provides crysta...  
WO/2018/038966A1
The present invention provides a pharmaceutical composition comprising a formulation of a corticosteroid and at least one organic acid and, optionally, a fast-acting insulin analog, in a vehicle. Also provided are methods to induce the p...  
WO/2018/034334A1
Provided is a therapeutic agent which effectively acts on diseases associated with abnormalities in dystroglycan sugar chain modification. A method for diagnosing diseases associated with abnormalities in dystroglycan sugar chain modific...  

Matches 51 - 100 out of 23,917